ERBB2 and breast cancer: Since HER2 has been shown to play a vital role in the development and progression of certain types of breast cancer, several novel anti-HER2 therapeutic agents, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine have been developed.